Project Grant R21AI188908
Award Date
11/20/24
Completion Date
10/31/26
Dollars Obligated
$507K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Bronx, NY 10461, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $843,620 to Albert Einstein College of Medicine to develop new broadly inhibitory antibody therapies against alphaviruses, a group of mosquito-transmitted viruses that can cause severe musculoskeletal disease and neurological conditions. The key objectives are to: 1) engineer Fc mutations into broadly protective antibodies to improve their in...
This federal Project Grant award of $2,370,939 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research into the molecular mechanisms governing chikungunya virus (CHIKV) binding, tropism, and pathogenesis. The primary objectives are to define the specific heparan sulfate (HS) structures required for CHIKV attachment and infection of target cells, identify the viral E2 protein residues...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $147,656 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Colorado-Denver. The project aims to elucidate the mechanisms driving the development of chronic Chikungunya virus (CHIKV) arthritis, a debilitating condition affecting up to 50% of CHIKV patients. The research will define the viral reservoir in macrophages, assess mechanisms driving pro-inflammatory...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $782,871 in funding to the University of Colorado-Denver to conduct research on the immune evasion mechanisms of arthritogenic alphavirus infections, such as Chikungunya and Ross River viruses. The key objectives of this 5-year research project are to: 1) investigate how type I interferon signaling in...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $318,085 to support research on the role of cell, antigen, and antibody in controlling virus infection through Fc-dependent mechanisms. The research aims to understand the molecular determinants that govern how natural killer (NK) cells control virus dissemination through antibody-dependent cellular...
The Project Grant award of $515,282.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to provide a detailed understanding of the molecular mechanisms underlying HIV spread through cell-to-cell contact. The research will leverage a novel flow cytometry assay and APEX proximity labeling technology to identify determinants and composition of the virological synapse, analyze how synapse formation...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $558,501 to support critical research into the Crimean-Congo Hemorrhagic Fever Virus (CCHFV). The primary awardee, Albert Einstein College of Medicine, is leading a collaborative effort to advance the understanding of CCHFV glycoprotein structure, assembly, and functions in viral entry, assembly, and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $681,755 to the Albert Einstein College of Medicine to delineate the mechanisms of intracellular assembly, maturation, trafficking, and activity of glycoprotein complexes from four rodent-infecting hantaviruses. The research aims to identify and define virus-host interactions required for endoplasmic...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 5-year, $170,640 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Washington University in St. Louis. The grant supports a career development program for Dr. Saravanan Raju, M.D., Ph.D., to establish an independent research career as an academic physician-scientist. The proposed research aims to study the basis of broad and durable immunity to arthritogenic alphaviruses,...
This $1,486,800 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research by Albert Einstein College of Medicine into antibody-dependent cell-mediated cytotoxicity (ADCC) for vaccine development against herpes simplex virus (HSV). The project aims to investigate the role of TNFRSF14 signaling in promoting ADCC responses and develop new strategies for future vaccine and...